Catalyst Wire Dossier Catalyst Wire Dossier

Civacir

polyclonal immune globulin (IgG) · Biotest Pharmaceuticals Corporation
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Civacir, covering 2012-02-07 to 2017-03-15. Get the full timeline:

Most recent: Clinical Trial Update: Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. [Phase 3]

See pricing